AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11821986
Drug: 1% aqueous
RxNorm normalized name: Zotane-HC 0.1%-1%-1% Aqueous Otic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% aqueous solution of poloxamine 1107 (treated)
Trial: 2758540
Drug: Neostigmine 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.04 mg.kg‐1 with varying doses of atropine (0.014 to 0.04 mg.kg‐1) in Group A
Trial: 2758540
Drug: Neostigmine 0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine 0.06 mg.kg‐1 with varying doses of atropine (0.02 to 0.04 mg.kg‐1) in Group B
Trial: 900826
Drug: 5000 units
RxNorm normalized name: A-25, 25000 units oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 units of subcutaneous heparin 2 hr before the operation, then 5000 units 3 times daily for 6 days
Trial: 900826
Drug: 5000 units
RxNorm normalized name: A-25, 25000 units oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 units of subcutaneous heparin
Trial: 19622685
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg nefiracetam per day
Trial: 19622685
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg nefiracetam per day
Trial: 16536342
Drug: Self-etching adhesives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-etching adhesives (AdheSE, Adper Prompt L-Pop, Clearfil SE Bond, iBond, OptiBond Solo Plus - Self-Etch Adhesive System, Xeno III)
Trial: 14641263
Drug: Levofloxacin 0.5%
RxNorm normalized name: LEVOFLOXACIN 0.5% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin 0.5% eye drops, one drop every 15 min for four doses prior to surgery
Trial: 14641263
Drug: Ciprofloxacin 0.3%
RxNorm normalized name: Ciprofloxacin 0.3%, Fluocinolone Acetonide 0.025% Otic drops, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 0.3% eye drops, one drop every 15 min for four doses prior to surgery
Trial: 9373657
Drug: Artesunate (intramuscular)
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Artesunate (intramuscular)
Trial: 1554153
Drug: Deproteinized hemodialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deproteinized hemodialysate 20% for infusion, 20 intra-arterial infusions over 4 weeks
Trial: 1554153
Drug: Bencyclan 250
RxNorm normalized name: bencyclane
DrugBank: Bencyclane (DB13488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bencyclan 250 mg in 250 mL saline 0.9%, 20 intra-arterial infusions over 4 weeks
Trial: 1554153
Drug: Deproteinized hemodialysate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deproteinized hemodialysate 20% for infusion
Trial: 29704456
Drug: 0.05% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% tretinoin cream applied three nights a week
Trial: 27930530
Drug: Remifentanil (infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (infused at 0.1 μg/kg/min and demand boluses of 0.1 μg/kg)
Trial: 21732113
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) at 830 nm, 86 mW, 92.1 J/cm², 0.25 J, 3 s/point, at 20 points, repeated every 48 hours for 14 days
Trial: 19099235
Drug: Dual release
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual release tablet (DRT-1) 300 mg
Trial: 19099235
Drug: Conventional immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional immediate release tablet (Daxfen, 300 mg)
Trial: 2132274
Drug: Chewable tablets
RxNorm normalized name: Pepcix Chewable Tablets
DrugBank: Bismuth subsalicylate (DB01294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chewable tablets containing pyridoxine and heat killed lactic bacteria
Trial: 513885
Drug: Self-administered health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered health history questionnaire (SAHHQ)
Trial: 6278914
Drug: Prolonged small
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged small dose propranolol (30 mg daily for 2 weeks)
Trial: 6278914
Drug: Serial dose
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial dose reduction of propranolol (for 6 to 9 days)
Trial: 6278914
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy (for 2 additional weeks after dose reduction)
Trial: 6278914
Drug: Prolonged small
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged small dose propranolol (30 mg daily)
Trial: 31359178
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g IA‐TXA
Trial: 31359178
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg IA‐TXA
Trial: 23272227
Drug: artesunate monotherapy
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: artesunate monotherapy (2 mg/kg/day)
Trial: 23272227
Drug: artesunate monotherapy
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: artesunate monotherapy (4 mg/kg/day)
Trial: 23272227
Drug: artesunate monotherapy
RxNorm normalized name: Artesunate
DrugBank: Artesunate (DB09274)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: artesunate monotherapy (2 mg/kg/day) and (4 mg/kg/day)
Trial: 9869669
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy (3 cycles of cisplatin and fluorouracil, followed by 2 additional cycles after surgery)
Trial: 7613890
Drug: Metronidazole 500
RxNorm normalized name: metronidazole 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole 500 mg intravenously 2 h before surgery
Trial: 2529072
Drug: Epidural sufentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural sufentanil 30, 50, or 75 micrograms per dose in 20 ml normal saline solution
Trial: 24154513
Drug: Fluticasone propionate/salmeterol
RxNorm normalized name: fluticasone propionate/salmeterol 100/50 MCG/INHAL Dry Powder Inhaler, 14 Blisters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluticasone propionate/salmeterol 250/50 µg, twice daily
Trial: 24154513
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 µg, twice daily
Trial: 19394976
Drug: pioglitazone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pioglitazone + metformin
Trial: 24874591
Drug: glimepiride +
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: glimepiride + metformin
Trial: 9483810
Drug: Ethinyl estradiol
RxNorm normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ethinyl estradiol (0.03 mg) plus dienogest (2 mg)
Trial: 9483810
Drug: Dienogest alone
RxNorm normalized name: Dienogest
DrugBank: Dienogest (DB09123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dienogest alone (0.5-2 mg/day)
Trial: 9483810
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen of dienogest, chlormadinone acetate, and desogestrel
Trial: 8141827
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA, mesalazine) 500 mg tid in slow release tablets (Salofalk)
Trial: 8141827
Drug: 5-aminosalicylic acid
RxNorm normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminosalicylic acid (5-ASA, mesalazine) 250 mg in slow release tablets (Salofalk)
Trial: 3707796
Drug: Morphine 2
RxNorm normalized name: apomorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 2 mg with adrenaline 50 micrograms
Trial: 3707796
Drug: Morphine 2
RxNorm normalized name: apomorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 2 mg without adrenaline (plain morphine)
Trial: 30782172
Drug: Placebo (informed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (informed that the capsule contained caffeine)
Trial: 29157808
Drug: Saffron (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saffron (15 mg/Bid)
Trial: 21704300
Drug: Preoperative β‐blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative β‐blockers
Trial: 21704300
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative β‐blockers
Trial: 16838611
Drug: KTP-Laser treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KTP-Laser treatment
Trial: 16838611
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (KTP-Laser + low-pressure TURP)
Trial: 12883779
Drug: Antiresorptive and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiresorptive and osteoanabolic drugs for osteoporosis treatment
Trial: 12883779
Drug: Treatment instituted
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment instituted during hospitalisation
Trial: 12883779
Drug: Continued treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued treatment monitored by family doctor
Trial: 11253344
Drug: High fixed
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High fixed doses of unfractionated heparin
Trial: 11253344
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of unfractionated heparin
Trial: 1320907
Drug: Intravenous granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous granisetron (40 micrograms/kg)
Trial: 1320907
Drug: Alizapride (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alizapride (4 mg/kg followed by 4 mg/kg at 4 and 8 h post-treatment) plus dexamethasone (8 mg)
Trial: 29855986
Drug: Ginkgo biloba
RxNorm normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginkgo biloba extract EGb 761® (120 mg, twice a day)
Trial: 29855986
Drug: Pentoxifylline (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (600 mg, twice a day)
Trial: 24585444
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of green tea (200 mL of 1.5%, w/v)
Trial: 24585444
Drug: Regular intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular intake of green tea (2 × 200 mL 1%, w/v per day for 7 days)
Trial: 24585444
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of green tea
Trial: 20808589
Drug: Immediate physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate physical therapy group (n = 16)
Trial: 20808589
Drug: Delayed physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed physical therapy group (n = 15)
Trial: 16103667
Drug: Granisetron +
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron + Alprazolam (G+A)
Trial: 16103667
Drug: Granisetron alone
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron alone (G)
Trial: 12186662
Drug: Diet history
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet history interviews and three‐day weighed food records administered at one‐month intervals in trial 1
Trial: 12186662
Drug: Diet history
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet history interviews and three‐day weighed food records administered at three‐month intervals in trial 2
Trial: 6376235
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Trestatin
Trial: 6376235
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg Trestatin
Trial: 6376235
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg Trestatin
Trial: 6376235
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Trestatin
Trial: 6376235
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Trestatin (diabetic patients)
Trial: 6376235
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Trestatin (diabetic patients)
Trial: 30741623
Drug: Edaravone therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Edaravone therapy
Trial: 30741623
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no edaravone therapy)
Trial: 26598090
Drug: Acarbose 100
RxNorm normalized name: acarbose 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acarbose 100 mg 3 times/day
Trial: 23491928
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous SAMe treatment (1,000mg for seven days)
Trial: 23491928
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standardized treatment)
Trial: 23491928
Drug: Postoperative intravenous
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative intravenous SAMe treatment
Trial: 21652619
Drug: Darunavir/ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir monotherapy (800/100 mg once daily)
Trial: 20002740
Drug: Xeomin® treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xeomin® treatment
Trial: 16440533
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 88 microg twice daily
Trial: 16440533
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 220 microg twice daily
Trial: 16440533
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate hydrofluoroalkane inhalation aerosol, 440 microg twice daily
Trial: 16440533
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate hydrofluoroalkane inhalation aerosol (all doses)
Trial: 11386892
Drug: Fenfluramine hydrochloride
RxNorm normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine hydrochloride (60 mg daily)
Trial: 9362431
Drug: Chemotherapy (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (standard combination regimens such as cyclophosphamide, methotrexate, and 5-fluorouracil; cyclophosphamide, doxorubicin, and 5-fluorouracil; mitoxantrone and 5-FU; single agents including paclitaxel and docetaxel)
Trial: 9362431
Drug: Hormonal therapy
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal therapy (aminoglutethimide, medroxyprogesterone acetate, tamoxifen, newer aromatase inhibitors such as anastrozole, fadrozole, and letrozole, megestrol acetate)
Trial: 1382676
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of zolpidem (Stilnox)
Trial: 25940151
Drug: PPI therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PPI therapy for 5 weeks after endoscopic resection (ER)
Trial: 18586835
Drug: FLGTN-HUT (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FLGTN-HUT (800 mcg, metred spray)
Trial: 11844897
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid 900 mg and metoclopramide 10 mg
Trial: 2314351
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of prostaglandin E1
Trial: 2314351
Drug: Intra-arterial infusion
RxNorm normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intra-arterial infusion of buflomedil
Trial: 2314351
Drug: Control conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control conditions (no infusion)
Trial: 476231
Drug: Dopamine-beta-hydroxylase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine-beta-hydroxylase inhibitor (fusaric acid) combined with L-dopa (500 mg)
Trial: 6407052
Drug: L-dopa alone
RxNorm normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-dopa alone
Trial: 15562885
Drug: Loratadine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loratadine (10 mg daily for 4 days)
Trial: 15562885
Drug: Cetirizine hydrochloride
RxNorm normalized name: Cetirizine Hydrochloride
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cetirizine hydrochloride (10 mg daily for 4 days)
Trial: 3044872
Drug: Codergocrine mesylate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codergocrine mesylate, increasing dosage over 12 weeks
Trial: 16153780
Drug: Intravenous acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen (1000mg)
Trial: 12816696
Drug: OAC triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OAC triple therapy
Trial: 1817628
Drug: Morphine 3
RxNorm normalized name: apomorphine 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 3 mg plus Clonidine 75 micrograms
Trial: 31842036
Drug: Topical 1.5%
RxNorm normalized name: phenol topical 1.5% topical liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1.5% Azithromycin (AZ) administered as a unit dose
Trial: 31842036
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no topical AZ)
Trial: 31823650
Drug: Daikenchuto (DKT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daikenchuto (DKT) 15 g extract granule daily for 4 weeks
Trial: 23359067
Drug: HM10460A 45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM10460A 45 μg/kg
Trial: 23359067
Drug: HM10460A 135
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM10460A 135 μg/kg
Trial: 23359067
Drug: HM10460A 350
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HM10460A 350 μg/kg
Trial: 21323679
Drug: Alcohol intoxication
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol intoxication (peak breath alcohol concentration of 0.11 ± 0.01 g%)
Trial: 17728695
Drug: Enteral glutamine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteral glutamine, 0.65 g kg(‐1) daily for 7 days
Trial: 16720935
Drug: Whole-body-vibration (WBV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body-vibration (WBV) treatment, 5 series of 60 seconds each
Trial: 16720935
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no WBV treatment)
Trial: 16720935
Drug: Whole-body-vibration (WBV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body-vibration (WBV) treatment (cross-over design)
Trial: 16720935
Drug: Whole-body-vibration (WBV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-body-vibration (WBV) treatment
Trial: 15533869
Drug: Baseline NT-proBNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline NT-proBNP levels >250 ng/L
Trial: 15533869
Drug: Lack of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lack of rapid decline in NT-proBNP levels (< or =250 ng/L)
Trial: 15533869
Drug: Rise in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rise in NT-proBNP levels over 72 hours to >250 ng/L
Trial: 9231658
Drug: Antecedent hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antecedent hypoglycemia of 3.9 mmol/l
Trial: 9231658
Drug: Antecedent hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antecedent hypoglycemia of 3.3 mmol/l
Trial: 9231658
Drug: Antecedent hypoglycemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antecedent hypoglycemia of 2.9 mmol/l
Trial: 8029784
Drug: Melipramine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melipramine (3 x 2 coated tablet) given in 60‐mg daily doses for 2 and 4 weeks